Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.
about
Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinomaHIV type-1 infection of the cotton rat (Sigmodon fulviventer and S. hispidus)Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIVChronic alcohol abuse and HIV disease progression: studies with the non-human primate modelRecent developments in human immunodeficiency virus-1 latency researchCritical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpoxModified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseasesRapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responsesGoing wild: lessons from naturally occurring T-lymphotropic lentivirusesReplication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategiesInhibition of adaptive immune responses leads to a fatal clinical outcome in SIV-infected pigtailed macaques but not vervet African green monkeys.Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimenEarly short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.Pathogenic features associated with increased virulence upon Simian immunodeficiency virus cross-species transmission from natural hosts.Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primatesSimian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease.Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatmentViral genetic evolution in macaques infected with molecularly cloned simian immunodeficiency virus correlates with the extent of persistent viremia.Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challengeContainment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatmentComparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIVRecombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.The intracytoplasmic domain of the Env transmembrane protein is a locus for attenuation of simian immunodeficiency virus SIVmac in rhesus macaques.Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.Intrinsic susceptibility of rhesus macaque peripheral CD4(+) T cells to simian immunodeficiency virus in vitro is predictive of in vivo viral replicationWide range of viral load in healthy african green monkeys naturally infected with simian immunodeficiency virus.Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in MacaquesProtection by live, attenuated simian immunodeficiency virus against heterologous challenge.High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis.Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicityResting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaquesA commonly recognized simian immunodeficiency virus Nef epitope presented to cytotoxic T lymphocytes of Indian-origin rhesus monkeys by the prevalent major histocompatibility complex class I allele Mamu-A*02.
P2860
Q24610485-A7FB56DE-1C5C-4B9D-9F83-0E81736226F6Q24651142-9D88CA16-6EE8-47B8-8C14-81EF5584175CQ24797123-88EE2C7C-20D6-462E-969D-E8780B43B83BQ26852432-85B64132-7D3E-4280-9572-A14B60CA78D6Q27013114-C8FA0180-441C-466C-A5A4-3A9976FC1BE7Q27346933-33F9747C-4F15-436A-B210-FC908308B837Q30209342-2609951C-7E82-4F3F-8275-2E614D86D138Q30354950-BC67EE45-50DC-42D8-93EE-8AA8B2CA9D81Q31066870-FC4C4CE5-3B9F-4D7B-B89A-34B8D0A386EDQ33187731-192A2C37-AABB-4882-BF3E-2B962D4F2B4FQ33320536-5D634F07-9906-4798-AE27-335B4FF9A3DFQ33440600-D17D3C14-9932-4273-8841-7F996B8D85CBQ33518502-3427AA06-27E4-48F0-BBFB-D63666233355Q33639684-8FB49E84-7D18-4CB3-9F27-F9115513394DQ33643898-E30A18E4-8793-4739-A33A-3988BA36C076Q33649657-8F4EAF0D-BBA6-4FEC-B5A6-89DADF691EA0Q33653655-7A6F3CF9-9F4E-4507-AE09-4A1406D354FCQ33743884-DCD238AB-9EB4-473E-BF7D-428842C2D57EQ33780685-C428A353-683F-4C1A-88D8-53DF77054575Q33782693-D1716A7C-C433-429D-BDE5-DBC2BDD0BDEAQ33782797-A826A042-B351-4E6B-BD4E-BDEC10994296Q33782843-009773CD-A82B-447C-B0B6-B75DAA6DFFC8Q33783429-511A12B3-DC36-44FC-A6C3-09487D47F382Q33784928-B52AF247-0382-4668-AA29-EA88FC48ED9EQ33799497-90D3CCC1-EB4C-4DE7-A7A5-DB8B61D36B65Q33799700-59CAA7B0-3F27-4554-B5B3-CF00A8BAF4DCQ33800033-88F2B275-BFB2-4C29-8287-C59C2D8D4AE6Q33800760-AE011913-4DA5-4090-98CF-E2123AC7A1EDQ33803714-46BDCF45-3CD9-4EE9-8115-FBA28752F12BQ33806370-01DB9274-0A41-416C-8F11-211D868C1ED1Q33809753-C275C72C-F39E-4BD6-ADC5-F68FBED0E3D6Q33811266-32E0FAFB-02CE-4345-A415-439FB1E4BD7AQ33812785-76968869-3B4F-40BD-8E11-5145622D46DBQ33813926-233EDC91-1111-4356-9951-69A7B64F2364Q33819493-7E276277-A8B6-4B63-9BA8-877E2D32F14EQ33820014-B3A76848-EBE1-408E-AB65-F84878F8E81FQ33825647-F63427A2-4F92-4123-9C8B-57B3A22D8858Q33834391-F1C09F3F-0CDE-4169-8396-A08453808B86Q33841288-D1FB66F6-CA58-4938-BAE6-8E92A5BB6499Q33847656-80F720BE-92F3-4084-B324-299C9F833CB2
P2860
Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Patterns of viral replication ...... odified vaccinia virus Ankara.
@ast
Patterns of viral replication ...... odified vaccinia virus Ankara.
@en
type
label
Patterns of viral replication ...... odified vaccinia virus Ankara.
@ast
Patterns of viral replication ...... odified vaccinia virus Ankara.
@en
prefLabel
Patterns of viral replication ...... odified vaccinia virus Ankara.
@ast
Patterns of viral replication ...... odified vaccinia virus Ankara.
@en
P2093
P2860
P1433
P1476
Patterns of viral replication ...... modified vaccinia virus Ankara
@en
P2093
D C Montefiori
J D Lifson
M W Carroll
S Goldstein
T R Fuerst
V M Hirsch
W G Alvord
P2860
P304
P407
P50
P577
1996-06-01T00:00:00Z